Form 4: Guardant Health Co-CEO Reports Future Equity Transactions

Guardant Health's Co-Chief Executive Officer, Helmy Eltoukhy, filed a Form 4 detailing planned equity transactions, including RSU vestings and new grants, scheduled for 2026.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), reported planned equity transactions for 2026 under a Rule 10b5-1 plan.
• On January 1, 2026, 13,209 shares of common stock will be transferred from direct ownership to the Helmy A. Eltoukhy Revocable Trust.
• Also on January 1, 2026, 38,283 restricted stock units (RSUs) from a March 12, 2025 grant will vest and convert into common stock.
• Concurrently on January 1, 2026, 19,402 shares will be withheld by the company at a price of $102.14 to cover tax obligations related to RSU vesting.
• On March 13, 2026, 26,961 performance-based restricted stock units (PBRSUs) will vest and convert into common stock.
• On the same date, March 13, 2026, 13,664 shares will be withheld by the company at a price of $85.49 for tax withholding purposes.
• On March 17, 2026, two new RSU awards will be granted: 11,268 RSUs vesting quarterly throughout 2026, and 101,409 RSUs vesting over three years starting January 1, 2027.
• Following these planned transactions, Eltoukhy's indirect beneficial ownership through the trust is projected to be 2,094,904 shares after the March 13, 2026 transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, primarily because the Co-CEO is receiving new, substantial RSU grants, indicating continued commitment and long-term incentive alignment, despite the routine tax-related share withholdings.

Positives

• Co-CEO Helmy Eltoukhy is receiving significant new RSU grants (11,268 and 101,409 RSUs) in March 2026, indicating continued long-term incentive and alignment with shareholder interests.
• The vesting of 38,283 RSUs and 26,961 performance-based RSUs demonstrates the achievement of prior compensation milestones.

Negatives

• A substantial number of shares (19,402 at $102.14 and 13,664 at $85.49) are being withheld by the company to cover tax obligations, which represents a reduction in the direct shareholding of the executive.

Future Outlook

The filing details future equity transactions for Helmy Eltoukhy, including the vesting schedule for existing and newly granted restricted stock units extending into 2027 and beyond. This indicates a continued long-term compensation structure for the Co-CEO.

Industry Context

StockSavvy.ai notes that the use of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs) as a significant component of executive compensation is a common practice across the biotechnology and healthcare technology sectors. This structure aims to align executive incentives with long-term shareholder value creation, as the value of these awards is tied to the company's stock performance. The pre-planned nature of these transactions via a Rule 10b5-1 plan is also standard practice for insiders to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• The compensation structure involving RSUs and PBRSUs for a Co-CEO in a growth-oriented biotech company like Guardant Health is consistent with industry benchmarks.
• Executives at peer companies such as Exact Sciences Corp. (EXAS) or Natera, Inc. (NTRA) often receive similar equity-based compensation packages designed to incentivize long-term performance and retention.
• The vesting schedules, particularly the multi-year vesting for the larger RSU grant, align with best practices for executive retention and performance alignment seen in companies of similar market capitalization and growth stage.

Related Party Transactions

• The transfer of 13,209 shares to the Helmy A. Eltoukhy Revocable Trust is a related party transaction, representing a change in the form of ownership for the reporting person.

Stakeholder Impact

• Shareholders: The vesting and granting of RSUs align executive incentives with shareholder interests, as the value of these awards is tied to the company's stock performance. Tax-related share withholdings slightly dilute outstanding shares but are a routine part of equity compensation.
• Employees: The filing details executive compensation, which can set a precedent or reflect the company's overall compensation philosophy.

Next Steps

• Vesting of remaining 67% of the March 12, 2025 RSU award in equal quarterly installments over two years after January 1, 2026.
• Quarterly vesting of the 11,268 RSU award on March 31, June 30, September 30, and December 31, 2026.
• Vesting of 33% of the 101,409 RSU award on January 1, 2027, with the remaining 67% vesting in equal quarterly installments over the subsequent two-year period.

Key Dates

Recommendation

This Form 4 details routine, pre-planned insider transactions related to executive compensation (RSU vesting and grants) and tax withholdings. It does not contain new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and reflect ongoing compensation structures.

Keywords

Guardant Health, GH, Helmy Eltoukhy, Form 4, SEC filing, insider trading, restricted stock units, RSU, equity compensation, stock vesting, executive compensation, Rule 10b5-1